NOTE

🌱 created from: bite_rrmm

monumental-1

• Design: Phase 1 study
• Number of patients: 232
• Patients characteristics: Heavily pretreated relapsed or refractory multiple myeloma patients
• Agent: Talquetamab, administered intravenously or subcutaneously in doses ranging from 0.5 to 180 μg per kilogram of body weight
• Treatment line: Patients who had received a median of six previous lines of therapy
• Trial Acronym: MonumenTAL-1, ClinicalTrials.gov number NCT03399799

Parameter	Result
Response rate	70% at 405 μg dose, 64% at 800 μg dose
Median duration of response	10.2 months at 405 μg dose, 7.8 months at 800 μg dose

• Highlight of toxicity: Common adverse events included cytokine release syndrome, skin-related events, and dysgeusia, primarily low-grade.
  • skin, nail, tounge
  • 味覺障礙（英語：Dysgeusia）指的是味覺的扭曲或失真。味覺障礙通常與喪失味覺、味覺遲鈍有關。味覺障礙可能是某個疾病的主要症狀或次要症狀。
• One line summary: Talquetamab showed significant response in heavily pretreated relapsed or refractory multiple myeloma patients with manageable toxicity.